Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 12c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.69), $0.12 better than the analyst estimate of ($0.81).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• Walmart shares fall despite earnings beat